All studies
Phase 3RecruitingInterventionalNCT07821944

A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate in Adults With Hyperlipidemia in India

  • Hyperlipidemia
  • Hypercholesterolemia
I want to take partRefer a patient2 sites in India · 2 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Merck Sharp & Dohme LLC
Enrolment target
150
Started
15 October 2026
Main results due (estimated)
26 November 2027
Study ends (estimated)
26 November 2027
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Triple (participant, investigator, outcomes assessor)
Sites
2 · 2 in India
First posted
16 September 2026
Registry updated
2 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* History of a major atherosclerotic cardiovascular disease (ASCVD) event or if no history of a major ASCVD event, has one or more of the following: possible or definite diagnosis of heterozygous familial hypercholesterolemia (HeFH), diabetes mellitus, stable angina pectoris, transient ischemic attack or symptomatic peripheral arterial disease
* Has a low-density lipoprotein cholesterol (LDL-C) ≥55 mg/dL or ≥70 mg/dL depending on medical history
* Is treated with a moderate- or high-intensity statin OR is treated with low-intensity statin with documentation of intolerance to a moderate or high-intensity statin OR is not receiving statins with documentation of statin intolerance
* If on any lipid-lowering therapies (LLTs), should be on a stable dose with no planned medication change

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Had a heart failure hospitalization within 3 months before Screening
* Has unstable angina, a myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening
* Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
* Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
* Has a history of nephrotic syndrome
* Has poorly controlled diabetes mellitus
* Has hyperthyroidism or inadequately controlled hypothyroidism
* Is actively receiving chemotherapy for malignancy or has a history of malignancy ≤3 years before Screening

What this study is about

In the sponsor’s own words, from the registry.

Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood.

Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol."

The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.

What participants receive

  • Experimental

    Enlicitide Decanoate

    Participants will receive 20 mg enlicitide decanoate orally once daily (qd) for up to 24 weeks.

    Drug: Enlicitide Decanoate

  • Other

    Placebo

    Participants will receive placebo orally qd for up to 24 weeks.

    Other: Placebo

Interventions

  • Enlicitide DecanoateDrug

    Also known as MK-0616, enlicitide

    Oral administration

  • PlaceboOther

    Oral administration

What the study measures

Primary outcomes

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess mean percent change in LDL-C.

    Time frame: Baseline and Week 24

  2. Number of Participants with One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 32 Weeks

  3. Number of Participants who Discontinue Study Drug Due to One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 24 Weeks

Secondary outcomes

  1. Mean Percent Change From Baseline in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess mean percent change in non-HDL-C.

    Time frame: Baseline and Week 24

  2. Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess mean percent change in ApoB.

    Time frame: Baseline and Week 24

  3. Percent Change From Baseline in Lipoprotein (a) (Lp(a)) at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess percent change in Lp(a)

    Time frame: Baseline and Week 24

  4. Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline.

    Time frame: Baseline and Week 24

  5. Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline.

    Time frame: Baseline and Week 24

Who is running it

Lead sponsor
Merck Sharp & Dohme LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Merck Sharp & Dohme LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
0616-038
  • Medical Director

    Study director

    Merck Sharp & Dohme LLC

Study sites(2)

  • KLES Prabhakar Kore Hospital & Medical Research Centre [M] ( Site 1004)

    Belagavi, Karnataka, India

    Recruiting

  • Sir Ganga Ram Hospital ( Site 1001)

    New Delhi, National Capital Territory of Delhi, India

    Recruiting

Showing 2 of 2 sites. 2 recruiting, 0 not recruiting and 0 cancelled; 2 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Source: ClinicalTrials.gov record NCT07821944, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.